Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, van 't Veer LJ.

Ann Oncol. 2010 Apr;21(4):717-22. doi: 10.1093/annonc/mdp388. Epub 2009 Oct 13.

PMID:
19825882
2.

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, Van't Veer LJ, Rutgers EJ.

Ann Surg Oncol. 2010 May;17(5):1406-13. doi: 10.1245/s10434-009-0902-x. Epub 2010 Jan 22.

PMID:
20094918
3.

Integrated gene expression profile predicts prognosis of breast cancer patients.

Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM.

Breast Cancer Res Treat. 2009 Jan;113(2):231-7. doi: 10.1007/s10549-008-9925-4. Epub 2008 Feb 16.

PMID:
18278552
4.

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium.

Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub 2008 Jul 27.

PMID:
18661261
5.

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ.

Breast Cancer Res Treat. 2010 Apr;120(3):655-61. doi: 10.1007/s10549-010-0814-2. Epub 2010 Mar 5.

PMID:
20204499
6.

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJ, van 't Veer LJ.

Br J Cancer. 2010 Dec 7;103(12):1788-93. doi: 10.1038/sj.bjc.6605916. Epub 2010 Nov 16.

7.

A gene-expression signature as a predictor of survival in breast cancer.

van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R.

N Engl J Med. 2002 Dec 19;347(25):1999-2009.

8.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC.

Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Erratum in: Lancet Oncol. 2008 Jan;9(1):10.

PMID:
18042430
9.

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ; TRANSBIG Consortium.

J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92.

PMID:
16954471
10.

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.

Drukker CA, Elias SG, Nijenhuis MV, Wesseling J, Bartelink H, Elkhuizen P, Fowble B, Whitworth PW, Patel RR, de Snoo FA, van 't Veer LJ, Beitsch PD, Rutgers EJ.

Breast Cancer Res Treat. 2014 Dec;148(3):599-613. doi: 10.1007/s10549-014-3188-z. Epub 2014 Nov 21. Erratum in: Breast Cancer Res Treat. 2015 Jan;149(2):567.

PMID:
25414025
11.

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.

Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, Chuang EY.

PLoS One. 2012;7(9):e45831. doi: 10.1371/journal.pone.0045831. Epub 2012 Sep 25.

12.

Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.

Martin KJ, Patrick DR, Bissell MJ, Fournier MV.

PLoS One. 2008 Aug 20;3(8):e2994. doi: 10.1371/journal.pone.0002994.

13.

Validation of 70-gene prognosis signature in node-negative breast cancer.

Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, van de Vijver MJ.

Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26.

PMID:
18819002
14.

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.

Bertucci F, Borie N, Roche H, Bachelot T, Le Doussal JM, Macgrogan G, Debono S, Martinec A, Treilleux I, Finetti P, Esterni B, Extra JM, Geneve J, Hermitte F, Chabannon C, Jacquemier J, Martin AL, Longy M, Maraninchi D, Fert V, Birnbaum D, Viens P.

Breast Cancer Res Treat. 2011 Jun;127(2):363-73. doi: 10.1007/s10549-010-1003-z. Epub 2010 Jun 29.

PMID:
20585850
15.

A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.

Kerr DA 2nd, Wittliff JL.

Horm Cancer. 2011 Oct;2(5):261-71. doi: 10.1007/s12672-011-0080-8.

PMID:
21826535
16.

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart M, Tursz T, Delaloge S, van't Veer L.

Breast. 2013 Oct;22(5):682-90. doi: 10.1016/j.breast.2012.12.002. Epub 2013 Jan 21.

PMID:
23347730
17.

A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.

Wan YW, Qian Y, Rathnagiriswaran S, Castranova V, Guo NL.

Oncol Rep. 2010 Aug;24(2):489-94.

18.

A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM.

Clin Cancer Res. 2008 Mar 15;14(6):1744-52. doi: 10.1158/1078-0432.CCR-07-1833.

19.

Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.

Liu NQ, Stingl C, Look MP, Smid M, Braakman RB, De Marchi T, Sieuwerts AM, Span PN, Sweep FC, Linderholm BK, Mangia A, Paradiso A, Dirix LY, Van Laere SJ, Luider TM, Martens JW, Foekens JA, Umar A.

J Natl Cancer Inst. 2014 Feb;106(2):djt376. doi: 10.1093/jnci/djt376. Epub 2014 Jan 7.

20.

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.

Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, Vrancken Peeters MJ, van Tinteren H, Van't Veer LJ, Rodenhuis S.

Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub 2009 Feb 13.

PMID:
19214742

Supplemental Content

Support Center